Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODURATE phase I study of biweekly TAS-102 + irinotecan + bevacizumab in refractory metastatic colorectal cancer
jRCTs041180028Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil, irinotecan and bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Dose limiting toxicity. Started Oct 2016; status: completed.
02
Drugs
trifluridine + tipiracilirinotecanbevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCTs041180028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180028.